UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 8, 2024
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code 781 -848-7100
(Former name or former address, if changed since last report.)
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): | |||||
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
| Securities registered pursuant to Section 12(b) of the Act: | ||||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | |||||
Emerging Growth Company | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | |||||
Item 2.02 Results of Operations and Financial Condition.
On February 8, 2024, Haemonetics Corporation issued a press release announcing financial results for the third quarter and nine months ended December 30, 2023. A copy of the press release is furnished with this report as Exhibit 99.1.
The foregoing information, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit Number | Description | |||||||
Press Release of Haemonetics Corporation dated February 8, 2024 announcing financial results for the third quarter and nine months ended December 30, 2023. | ||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HAEMONETICS CORPORATION | ||||||||||||||
Date: February 8, 2024 | By: | /s/ Christopher A. Simon | ||||||||||||
| Name: | Christopher A. Simon | |||||||||||||
| Title: | President and Chief Executive Officer | |||||||||||||
| Exhibit 99.1 | |||||
| Investor Contacts | Media Contact | ||||
| Olga Guyette, Sr. Director-Investor Relations & Treasury | Josh Gitelson, Director-Communications | ||||
| (781) 356-9763 | (781) 356-9776 | ||||
| olga.guyette@haemonetics.com | josh.gitelson@haemonetics.com | ||||
| David Trenk, Manager-Investor Relations | |||||
| (203) 733-4987 | |||||
| david.trenk@haemonetics.com | |||||
Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2024 Results; Updates Fiscal 2024 Guidance
Boston, MA, February 8, 2024 - Haemonetics Corporation (NYSE: HAE) reported financial results for its third quarter and year-to-date fiscal 2024, which ended December 30, 2023:
3rd Quarter 2024 | YTD 2024 | |||||||||||||
| n | Revenue, increase | $336 million, 10% | $966 million, 12% | |||||||||||
| n | Organic1 revenue increase | 10% | 12% | |||||||||||
| n | Earnings per diluted share | $0.61 | $1.89 | |||||||||||
| n | Adjusted earnings per diluted share | $1.04 | $3.07 | |||||||||||
| n | Cash (out)flow from operating activities | ($1) million | $118 million | |||||||||||
| n | Free cash (out)flow before restructuring & restructuring related costs | ($20) million | $68 million | |||||||||||
1 Excludes the impact of currency fluctuation and the acquisition of the Sensor Guided Technologies product line in December 2023. | ||||||||||||||
Chris Simon, Haemonetics’ CEO, stated: "We continue to deliver increased revenue and margins, strengthen market leadership and increase impact through portfolio evolution, operational excellence and resource allocation. Outperformance is funding additional opportunities for accelerated growth and diversification like the OpSens acquisition. We are well-positioned and gaining momentum to achieve long-term transformational growth."
GAAP RESULTS
Third quarter fiscal 2024 revenue was $336.3 million, up 10.1% compared with the third quarter of fiscal 2023. Business unit revenue and growth rates compared with the prior year period were as follows:
| ($ millions) | 3rd Quarter 2024 Reported | |||||||
| Plasma | $146.8 | 8.4% | ||||||
| Blood Center | $70.5 | (3.9)% | ||||||
| Hospital | $113.4 | 23.9% | ||||||
| Net business unit revenue | $330.7 | 10.1% | ||||||
| Service | $5.6 | 12.8% | ||||||
| Total net revenue | $336.3 | 10.1% | ||||||
1
Gross margin was 52.9% in the third quarter of fiscal 2024 compared with 52.0% in the third quarter of fiscal 2023. The primary drivers of the increase in the gross margin percentage were volume, mix and price, partially offset by portfolio rationalization initiatives, continuous growth investments and increased depreciation expense. Operating expenses as a percentage of revenue were 39.2% in the third quarter of fiscal 2024 compared with 37.8% in the third quarter of fiscal 2023. The increase in operating expenses as a percentage of revenue was primarily driven by continuous growth investments, transaction costs and digital transformation costs, partially offset by operating leverage. The Company had operating income of $46.0 million and a 13.7% operating margin in the third quarter of fiscal 2024, compared with operating income of $43.3 million and an operating margin of 14.2% in the third quarter of fiscal 2023. The income tax rates were 29% and 22% in the third quarters of fiscal 2024 and fiscal 2023, respectively. Third quarter fiscal 2024 net income and earnings per diluted share were $31.2 million and $0.61, respectively, compared with $32.9 million and $0.64, respectively, in the third quarter of fiscal 2023.
ADJUSTED RESULTS
Organic revenue for the third quarter of fiscal 2024 was up 9.7% compared with the same period of fiscal 2023. Business unit organic revenue growth rates compared with the prior year period were as follows:
| 3rd Quarter 2024 Organic | |||||
| Plasma | 8.1% | ||||
| Blood Center | (2.6)% | ||||
| Hospital | 21.6% | ||||
| Net business unit revenue | 9.6% | ||||
| Service | 10.9% | ||||
| Total net revenue | 9.7% | ||||
Third quarter fiscal 2024 adjusted gross margin was 55.3%, up 280 basis points compared with the prior year period. The primary drivers of the increase in the adjusted gross margin percentage were price, volume and mix, partially offset by continuous growth investments and higher depreciation expense.
Adjusted operating expenses as a percentage of revenue were 33.5% in the third quarter of fiscal 2024, compared with 33.2% in the third quarter of fiscal 2023. The increase in adjusted operating expenses as a percentage of revenue was primarily driven by continuous growth investments and higher performance-based compensation, partially offset by stronger operating leverage. Adjusted operating income for the third quarter of fiscal 2024 was $73.4 million, up $14.4 million or 24.3%, compared with the third quarter of fiscal 2023. Adjusted operating margin was 21.8%, up 250 basis points when compared with the same period of fiscal 2023. The adjusted income tax rates were 25% in the third quarters of both fiscal 2024 and fiscal 2023.
Third quarter fiscal 2024 adjusted net income was $53.3 million, up $9.7 million, or 22.3%, and adjusted earnings per diluted share was $1.04, up 22.4%, when compared with the same period of fiscal 2023.
2
RESTRUCTURING, AMORTIZATION OF ACQUIRED INTANGIBLE ASSETS, TRANSACTION COSTS AND DIGITAL TRANSFORMATION COSTS.
The Company recorded amortization of acquired intangible assets of $6.9 million in the third quarter of fiscal 2024 compared with $8.1 million in the third quarter of fiscal 2023. The Company also incurred $8.0 million in restructuring charges primarily for portfolio rationalization initiatives, $4.9 million in transaction costs in connection with the OpSens, Inc. acquisition and $3.4 million of digital transformation costs related to the upgrade of our enterprise resource planning system in the third quarter of fiscal 2024.
BALANCE SHEET AND CASH FLOW
Cash on hand at December 30, 2023 was $194.0 million, a decrease of $90.5 million since April 1, 2023, primarily driven by the OpSens, Inc. acquisition.
Cash outflow from operating activities was $0.5 million and free cash outflow before restructuring and restructuring related costs was $20.3 million during the third quarter of fiscal 2024, compared with operating cash flow of $64.4 million and free cash flow before restructuring and restructuring related costs of $52.8 million, respectively, in the same period of fiscal 2023. The drivers of both operating cash outflow and free cash outflow before restructuring and restructuring related costs were the timing of customer payments, decreases in accounts payable and increased inventory balances.
FISCAL 2024 GUIDANCE
The Company updated its previous fiscal 2024 GAAP total revenue and organic revenue growth guidance as follows:
| Total Company | Previous Guidance | Current Guidance | ||||||||||||
| Reported | 8 - 10% | 10 - 12% | ||||||||||||
| Currency impact | (1)% | (1)% | ||||||||||||
| Acquisition | 1% | 1% | ||||||||||||
| Organic | 8 - 10% | 10 - 12% | ||||||||||||
| Business unit organic revenue | Previous Guidance | Current Guidance | ||||||||||||
| Plasma revenue | 10 - 12% | 11 - 13% | ||||||||||||
| Blood Center revenue | (2 - 4)% | (0 - 2)% | ||||||||||||
| Hospital revenue | 16 - 18% | 16 - 18% | ||||||||||||
3
Additionally, the Company reaffirmed its adjusted operating margin guidance, and updated its adjusted earnings per diluted share guidance and free cash flow before restructuring and restructuring related costs guidance as follows:
| Previous Guidance | Current Guidance | ||||||||||
Adjusted operating margin | ~21% | ~21% | |||||||||
Adjusted earnings per diluted share | $3.75 - $3.95 | $3.90 - $4.00 | |||||||||
Free cash flow, before restructuring & restructuring related costs | $170M - $190M | $160M - $180M | |||||||||
WEBCAST CONFERENCE CALL AND RESULTS ANALYSIS
The Company will host a conference call with investors and analysts to discuss third quarter fiscal 2024 results on Thursday, February 8, 2024 at 8:00 a.m. ET. The call can be accessed via teleconference at https://register.vevent.com/register/BIddeef4a5eb8d4c2d96bcf82386d2a73e. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
Alternatively, a live webcast of the call can be accessed on Haemonetics’ investor relations website at the following direct link: https://edge.media-server.com/mmc/p/unynzc8w
ABOUT HAEMONETICS
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.
FORWARD-LOOKING STATEMENTS
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without limitation, statements regarding (i) plans and objectives of management for operations of the Company, including plans or objectives related to the development and commercialization of, and regulatory approvals related to, the Company’s products and plans or objectives related to the Company’s Operational Excellence Program and portfolio rationalization initiatives; (ii) estimates or projections of financial results, financial condition, capital expenditures, capital structure or other financial items, including with respect to the share repurchase program; (iii) the impact of inflationary pressures in our global manufacturing and supply chain; and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as
4
a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, availability and demand for the Company’s products; the Company’s ability to implement as planned and realize estimated cost savings from the Operational Excellence Program and portfolio rationalization initiatives; inflationary pressures, rising interest rates and macroeconomic conditions; the Company’s ability to execute business continuity plans; risks arising from planned or completed acquisitions or divestitures by the Company, including any failure to realize the anticipated strategic benefits and opportunities of such transactions; the impact of share repurchases on the Company’s stock price and volatility as well as the effect of short-term price fluctuations on the share repurchase program’s effectiveness; technological advances in the medical field and standards for transfusion medicine and the Company’s ability to successfully offer products that incorporate such advances and standards; product quality; market acceptance; regulatory uncertainties, including in the receipt or timing of regulatory approvals; the effect of economic and political conditions; the impact of competitive products and pricing; blood product reimbursement policies and practices; and the effect of industry consolidation as seen in the plasma market. These and other factors are identified and described in more detail in the Company’s periodic reports and other filings with the U.S. Securities and Exchange Commission (the “SEC”). The Company does not undertake to update these forward-looking statements.
MANAGEMENT’S USE OF NON-GAAP MEASURES
This press release contains financial measures that are considered “non-GAAP” financial measures under applicable SEC rules and regulations. Management uses non-GAAP measures to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results. Performance targets for management are also based on certain non-GAAP financial measures. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company’s reported financial results prepared in accordance with U.S. GAAP. In this release, supplemental non-GAAP measures have been provided to assist investors in evaluating the performance of the Company’s core operations and provide a baseline for analyzing trends in the Company’s underlying businesses. We strongly encourage investors to review the Company’s financial statements and publicly-filed reports in their entirety and not rely on any single financial measure.
When used in this release, organic revenue growth excludes the impact of currency fluctuation and acquisitions. Adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted provision for income taxes, adjusted net income and adjusted earnings per diluted share exclude restructuring costs, restructuring related costs, digital transformation costs, amortization of acquired intangible assets, asset impairments, accelerated device depreciation and related costs, costs related to compliance with the European Union Medical Device Regulation ("MDR") and In Vitro Diagnostic Regulation ("IVDR"), integration and transaction costs, certain tax settlements and unusual or infrequent and material litigation-related charges. Adjusted net income and adjusted earnings per diluted share also exclude the tax impact of these items. The adjustments to provision for income taxes are calculated based on the jurisdictions in which pre-tax adjustments occurred. Free cash flow before restructuring
5
and restructuring related costs is defined as cash provided by operating activities less capital expenditures, net of the proceeds from the sale of property, plant and equipment and restructuring and restructuring related costs, net of tax. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to similarly titled measures used by other companies.
A reconciliation of non-GAAP historical financial measures to their most comparable GAAP measure are included at the end of the financial sections of this press release as well as on the Company’s website at www.haemonetics.com. The Company does not provide a quantitative reconciliation of its forward-looking organic revenue growth guidance by business unit to the comparable GAAP measure because forecasting the impact of foreign currency fluctuations by business unit is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. Additionally, the Company does not attempt to provide reconciliations of forward-looking adjusted operating margin guidance, adjusted earnings per diluted share guidance or free cash flow before restructuring and restructuring related costs guidance to the comparable GAAP measures because the combined impact and timing of recognition of certain potential charges or gains, such as restructuring costs and impairment charges, is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of the Company’s financial performance.
6
| Haemonetics Corporation Financial Summary | ||||||||||||||||||||||||||||||||||||||
| Condensed Consolidated Statements of Income | ||||||||||||||||||||||||||||||||||||||
| (Data in thousands, except per share data) | ||||||||||||||||||||||||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||||||||||||||
| 12/30/2023 | 12/31/2022 | Inc/(Dec) % | 12/30/2023 | 12/31/2022 | Inc/(Dec) % | |||||||||||||||||||||||||||||||||
| (unaudited) | (unaudited) | |||||||||||||||||||||||||||||||||||||
| Net revenues | $ | 336,250 | $ | 305,301 | 10.1% | $ | 965,765 | $ | 864,244 | 11.7% | ||||||||||||||||||||||||||||
| Cost of goods sold | 158,383 | 146,594 | 8.0% | 450,123 | 405,396 | 11.0% | ||||||||||||||||||||||||||||||||
| Gross profit | 177,867 | 158,707 | 12.1% | 515,642 | 458,848 | 12.4% | ||||||||||||||||||||||||||||||||
| Research and development | 13,265 | 12,689 | 4.5% | 38,578 | 34,487 | 11.9% | ||||||||||||||||||||||||||||||||
| Selling, general and administrative | 111,713 | 94,661 | 18.0% | 310,099 | 278,917 | 11.2% | ||||||||||||||||||||||||||||||||
| Amortization of acquired intangible assets | 6,911 | 8,078 | (14.4)% | 21,606 | 24,666 | (12.4)% | ||||||||||||||||||||||||||||||||
| Impairment of intangible assets | — | — | n/m | 10,419 | — | n/m | ||||||||||||||||||||||||||||||||
| Operating expenses | 131,889 | 115,428 | 14.3% | 380,702 | 338,070 | 12.6% | ||||||||||||||||||||||||||||||||
| Operating income | 45,978 | 43,279 | 6.2% | 134,940 | 120,778 | 11.7% | ||||||||||||||||||||||||||||||||
| Interest and other expense, net | (1,949) | (1,055) | 84.7% | (6,489) | (12,001) | (45.9)% | ||||||||||||||||||||||||||||||||
| Income before taxes | 44,029 | 42,224 | 4.3% | 128,451 | 108,777 | 18.1% | ||||||||||||||||||||||||||||||||
| Provision for income taxes | 12,788 | 9,280 | 37.8% | 31,260 | 22,759 | 37.4% | ||||||||||||||||||||||||||||||||
| Net income | $ | 31,241 | $ | 32,944 | (5.2)% | $ | 97,191 | $ | 86,018 | 13.0% | ||||||||||||||||||||||||||||
| Net income per common share assuming dilution | $ | 0.61 | $ | 0.64 | (4.7)% | $ | 1.89 | $ | 1.67 | 13.2% | ||||||||||||||||||||||||||||
| Weighted average number of shares: | ||||||||||||||||||||||||||||||||||||||
| Basic | 50,768 | 50,509 | 50,679 | 50,896 | ||||||||||||||||||||||||||||||||||
| Diluted | 51,445 | 51,219 | 51,394 | 51,487 | ||||||||||||||||||||||||||||||||||
| Profit Margins: | Inc/(Dec) % | Inc/(Dec) % | ||||||||||||||||||||||||||||||||||||
| Gross profit | 52.9 | % | 52.0 | % | 0.9% | 53.4 | % | 53.1 | % | 0.3% | ||||||||||||||||||||||||||||
| Research and development | 3.9 | % | 4.2 | % | (0.3)% | 4.0 | % | 4.0 | % | —% | ||||||||||||||||||||||||||||
| Selling, general and administrative | 33.2 | % | 31.0 | % | 2.2% | 32.1 | % | 32.3 | % | (0.2)% | ||||||||||||||||||||||||||||
| Operating income | 13.7 | % | 14.2 | % | (0.5)% | 14.0 | % | 14.0 | % | —% | ||||||||||||||||||||||||||||
| Income before taxes | 13.1 | % | 13.8 | % | (0.7)% | 13.3 | % | 12.6 | % | 0.7% | ||||||||||||||||||||||||||||
| Net income | 9.3 | % | 10.8 | % | (1.5)% | 10.1 | % | 10.0 | % | 0.1% | ||||||||||||||||||||||||||||
7
| Revenue Analysis by Business Unit | ||||||||||||||||||||||||||||||||||||||
| (Data in thousands) | ||||||||||||||||||||||||||||||||||||||
| Three Months Ended | ||||||||||||||||||||||||||||||||||||||
| 12/30/2023 | 12/31/2022 | Reported growth | Currency impact | Acquisition(1) | Organic growth | |||||||||||||||||||||||||||||||||
| Revenues by business unit | (unaudited) | |||||||||||||||||||||||||||||||||||||
Plasma(2) | $ | 146,805 | $ | 135,461 | 8.4 | % | 0.3 | % | — | % | 8.1 | % | ||||||||||||||||||||||||||
| Apheresis | 50,666 | 52,398 | (3.3) | % | (1.9) | % | — | % | (1.4) | % | ||||||||||||||||||||||||||||
| Whole Blood | 19,814 | 20,964 | (5.5) | % | 0.1 | % | — | % | (5.6) | % | ||||||||||||||||||||||||||||
| Blood Center | 70,480 | 73,362 | (3.9) | % | (1.3) | % | — | % | (2.6) | % | ||||||||||||||||||||||||||||
Interventional Technologies(3) | 43,007 | 32,154 | 33.8 | % | (0.2) | % | 6.1 | % | 27.9 | % | ||||||||||||||||||||||||||||
| Blood Management Technologies: | ||||||||||||||||||||||||||||||||||||||
| Hemostasis Management | 41,423 | 34,921 | 18.6 | % | 0.1 | % | — | % | 18.5 | % | ||||||||||||||||||||||||||||
Other(3) | 28,989 | 24,485 | 18.4 | % | 0.4 | % | — | % | 18.0 | % | ||||||||||||||||||||||||||||
| Hospital | 113,419 | 91,560 | 23.9 | % | 0.1 | % | 2.2 | % | 21.6 | % | ||||||||||||||||||||||||||||
| Net business unit revenues | 330,704 | 300,383 | 10.1 | % | (0.2) | % | 0.7 | % | 9.6 | % | ||||||||||||||||||||||||||||
| Service | 5,546 | 4,918 | 12.8 | % | 1.9 | % | — | % | 10.9 | % | ||||||||||||||||||||||||||||
| Total net revenues | $ | 336,250 | $ | 305,301 | 10.1 | % | (0.2) | % | 0.6 | % | 9.7 | % | ||||||||||||||||||||||||||
| Nine Months Ended | ||||||||||||||||||||||||||||||||||||||
| 12/30/2023 | 12/31/2022 | Reported growth | Currency impact | Acquisition(1) | Organic growth | |||||||||||||||||||||||||||||||||
| Revenues by business unit | (unaudited) | |||||||||||||||||||||||||||||||||||||
Plasma(2) | $ | 427,315 | $ | 365,735 | 16.8 | % | 0.1 | % | — | % | 16.7 | % | ||||||||||||||||||||||||||
| Apheresis | 151,380 | 152,287 | (0.6) | % | (3.0) | % | — | % | 2.4 | % | ||||||||||||||||||||||||||||
| Whole Blood | 54,538 | 60,452 | (9.8) | % | (0.7) | % | — | % | (9.1) | % | ||||||||||||||||||||||||||||
| Blood Center | 205,918 | 212,739 | (3.2) | % | (2.3) | % | — | % | (0.9) | % | ||||||||||||||||||||||||||||
Interventional Technologies(3) | 119,169 | 91,297 | 30.5 | % | (0.2) | % | 2.2 | % | 28.5 | % | ||||||||||||||||||||||||||||
| Blood Management Technologies: | ||||||||||||||||||||||||||||||||||||||
| Hemostasis Management | 116,241 | 102,737 | 13.1 | % | (0.7) | % | — | % | 13.8 | % | ||||||||||||||||||||||||||||
Other(4) | 80,760 | 76,875 | 5.1 | % | (0.7) | % | — | % | 5.8 | % | ||||||||||||||||||||||||||||
| Hospital | 316,170 | 270,909 | 16.7 | % | (0.6) | % | 0.8 | % | 16.5 | % | ||||||||||||||||||||||||||||
| Net business unit revenues | 949,403 | 849,383 | 11.8 | % | (0.7) | % | 0.2 | % | 12.3 | % | ||||||||||||||||||||||||||||
| Service | 16,362 | 14,861 | 10.1 | % | 0.7 | % | — | % | 9.4 | % | ||||||||||||||||||||||||||||
| Total net revenues | $ | 965,765 | $ | 864,244 | 11.7 | % | (0.7) | % | 0.2 | % | 12.2 | % | ||||||||||||||||||||||||||
(1) Reflects the impact in Hospital of the Sensor Guided Technologies product line acquired as part of the OpSens, Inc. transaction in December 2023. | ||||||||||||||||||||||||||||||||||||||
(2) Plasma had organic revenue growth of 8.4% and 17.1% in North America for the three and nine months ended December 30, 2023, respectively, and 7.0% and 17.0% of organic revenue growth in North America disposables for the three and nine months ended December 30, 2023, respectively. | ||||||||||||||||||||||||||||||||||||||
(3) Interventional Cardiology includes Vascular Closure and Sensor Guided Technologies product lines of the Hospital business unit. | ||||||||||||||||||||||||||||||||||||||
(4) Other includes the Cell Salvage and Transfusion Management product lines of the Hospital business unit. | ||||||||||||||||||||||||||||||||||||||
8
| Condensed Consolidated Balance Sheets | |||||||||||||||||
| (Data in thousands) | |||||||||||||||||
| As of | |||||||||||||||||
| 12/30/2023 | 4/1/2023 | ||||||||||||||||
| (unaudited) | |||||||||||||||||
| Assets | |||||||||||||||||
| Cash and cash equivalents | $ | 193,978 | $ | 284,466 | |||||||||||||
| Accounts receivable, net | 211,611 | 179,142 | |||||||||||||||
| Inventories, net | 304,024 | 259,379 | |||||||||||||||
| Other current assets | 55,369 | 46,735 | |||||||||||||||
| Total current assets | 764,982 | 769,722 | |||||||||||||||
| Property, plant & equipment, net | 318,665 | 310,885 | |||||||||||||||
| Intangible assets, net | 429,270 | 275,771 | |||||||||||||||
| Goodwill | 554,999 | 466,231 | |||||||||||||||
| Other assets | 132,512 | 112,216 | |||||||||||||||
| Total assets | $ | 2,200,428 | $ | 1,934,825 | |||||||||||||
| Liabilities & Stockholders' Equity | |||||||||||||||||
| Short-term debt & current maturities | $ | 13,736 | $ | 11,784 | |||||||||||||
| Other current liabilities | 248,019 | 240,032 | |||||||||||||||
| Total current liabilities | 261,755 | 251,816 | |||||||||||||||
| Long-term debt | 856,849 | 754,102 | |||||||||||||||
| Other long-term liabilities | 138,505 | 110,910 | |||||||||||||||
| Stockholders' equity | 943,319 | 817,997 | |||||||||||||||
| Total liabilities & stockholders' equity | $ | 2,200,428 | $ | 1,934,825 | |||||||||||||
9
| Condensed Consolidated Statements of Cash Flows | |||||||||||
| (Data in thousands) | |||||||||||
| Nine Months Ended | |||||||||||
| 12/30/2023 | 12/31/2022 | ||||||||||
| (unaudited) | |||||||||||
| Cash Flows from Operating Activities: | |||||||||||
| Net income | $ | 97,191 | $ | 86,018 | |||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Depreciation and amortization | 69,576 | 69,453 | |||||||||
| Share-based compensation expense | 20,912 | 18,525 | |||||||||
| Impairment of intangible assets | 10,419 | 94 | |||||||||
| Amortization of deferred financing costs | 2,393 | 1,098 | |||||||||
| Inventory reserve adjustment | 6,904 | 483 | |||||||||
| Change in other non-cash operating activities | (2,430) | 160 | |||||||||
| Change in accounts receivable, net | (27,743) | (24,370) | |||||||||
| Change in inventories, net | (40,721) | 34,506 | |||||||||
| Change in other working capital | (18,831) | 7,480 | |||||||||
| Net cash provided by operating activities | 117,670 | 193,447 | |||||||||
| Cash Flows from Investing Activities: | |||||||||||
| Capital expenditures | (56,611) | (98,272) | |||||||||
| Acquisitions | (243,852) | (2,850) | |||||||||
| Proceeds from divestiture | — | 850 | |||||||||
| Proceeds from sale of property, plant and equipment | 1,259 | 7,695 | |||||||||
| Other investments | (10,129) | (33,205) | |||||||||
| Net cash used in investing activities | (309,333) | (125,782) | |||||||||
| Cash Flows from Financing Activities: | |||||||||||
| Repayments, net of borrowings | 101,250 | (7,875) | |||||||||
| Debt issuance costs | — | (1,118) | |||||||||
| Share repurchases | — | (75,000) | |||||||||
| Contingent consideration payments | (849) | (21,593) | |||||||||
| Proceeds from employee stock programs | 7,108 | 6,857 | |||||||||
| Cash used to net share settle employee equity awards | (5,885) | — | |||||||||
| Other financing activities | 35 | (32) | |||||||||
| Net cash provided by (used in) financing activities | 101,659 | (98,761) | |||||||||
| Effect of exchange rates on cash and cash equivalents | (484) | (4,398) | |||||||||
| Net Change in Cash and Cash Equivalents | (90,488) | (35,494) | |||||||||
| Cash and Cash Equivalents at Beginning of the Period | 284,466 | 259,496 | |||||||||
| Cash and Cash Equivalents at End of Period | $ | 193,978 | $ | 224,002 | |||||||
| Free Cash Flow Reconciliation: | |||||||||||
| Cash provided by operating activities | $ | 117,670 | $ | 193,447 | |||||||
| Capital expenditures, net of proceeds from sale of property, plant and equipment | (55,352) | (90,577) | |||||||||
| Free cash flow after restructuring and restructuring related costs | 62,318 | 102,870 | |||||||||
| Restructuring and restructuring related costs | 7,772 | 20,386 | |||||||||
| Tax benefit on restructuring and restructuring related costs | (1,655) | (4,241) | |||||||||
| Free cash flow before restructuring and restructuring related costs | $ | 68,435 | $ | 119,015 | |||||||
10
Reconciliation of Adjusted Measures for Third Quarter of FY24 and FY23 | ||||||||||||||||||||||||||||||||||||||
| (Data in thousands, except per share data) | ||||||||||||||||||||||||||||||||||||||
Three Months Ended December 30, 2023: | Gross profit | Operating expenses | Operating income | Provision for income taxes | Net income | Earnings per diluted share | ||||||||||||||||||||||||||||||||
| Reported | $ | 177,867 | $ | 131,889 | $ | 45,978 | $ | 12,788 | $ | 31,241 | $ | 0.61 | ||||||||||||||||||||||||||
| Amortization of acquired intangible assets | — | (6,911) | 6,911 | 1,912 | 4,999 | 0.10 | ||||||||||||||||||||||||||||||||
| Integration and transaction costs | — | (4,869) | 4,869 | (410) | 5,279 | 0.10 | ||||||||||||||||||||||||||||||||
| Restructuring costs | 7,065 | (903) | 7,968 | 1,775 | 6,193 | 0.12 | ||||||||||||||||||||||||||||||||
| Restructuring related costs | 1,125 | (1,278) | 2,403 | 618 | 1,785 | 0.04 | ||||||||||||||||||||||||||||||||
| Digital transformation costs | — | (3,415) | 3,415 | 910 | 2,505 | 0.05 | ||||||||||||||||||||||||||||||||
| Impairment of assets and PCS2 related charges | 49 | (161) | 210 | 58 | 152 | — | ||||||||||||||||||||||||||||||||
| MDR and IVDR costs | — | (1,433) | 1,433 | 365 | 1,068 | 0.02 | ||||||||||||||||||||||||||||||||
| Litigation-related charges | — | (177) | 177 | 122 | 55 | — | ||||||||||||||||||||||||||||||||
| Adjusted | $ | 186,106 | $ | 112,742 | $ | 73,364 | $ | 18,138 | $ | 53,277 | $ | 1.04 | ||||||||||||||||||||||||||
| Adjusted, as a percentage of net revenues | 55.3 | % | 33.5 | % | 21.8 | % | 15.8 | % | ||||||||||||||||||||||||||||||
Three Months Ended December 31, 2022: | Gross profit | Operating expenses | Operating income | Provision for income taxes | Net income | Earnings per diluted share | ||||||||||||||||||||||||||||||||
| Reported | $ | 158,707 | $ | 115,428 | $ | 43,279 | $ | 9,280 | $ | 32,944 | $ | 0.64 | ||||||||||||||||||||||||||
| Amortization of acquired intangible assets | — | (8,078) | 8,078 | 2,427 | 5,651 | 0.11 | ||||||||||||||||||||||||||||||||
| Integration and transaction costs | — | (287) | 287 | 86 | 201 | — | ||||||||||||||||||||||||||||||||
| Restructuring costs | (49) | (93) | 44 | 13 | 31 | — | ||||||||||||||||||||||||||||||||
| Restructuring related costs | 1,847 | (2,234) | 4,081 | 1,199 | 2,882 | 0.07 | ||||||||||||||||||||||||||||||||
| Impairment of assets and PCS2 related charges | (122) | (120) | (2) | — | (2) | — | ||||||||||||||||||||||||||||||||
| MDR and IVDR costs | 11 | (2,472) | 2,483 | 703 | 1,780 | 0.03 | ||||||||||||||||||||||||||||||||
| Litigation-related charges | — | (757) | 757 | 227 | 530 | 0.01 | ||||||||||||||||||||||||||||||||
| Discrete tax adjustments | — | — | — | 457 | (457) | (0.01) | ||||||||||||||||||||||||||||||||
| Adjusted | $ | 160,394 | $ | 101,387 | $ | 59,007 | $ | 14,392 | $ | 43,560 | $ | 0.85 | ||||||||||||||||||||||||||
| Adjusted, as a percentage of net revenues | 52.5 | % | 33.2 | % | 19.3 | % | 14.3 | % | ||||||||||||||||||||||||||||||
11
| Reconciliation of Adjusted Measures for Year-to-Date FY24 and FY23 | ||||||||||||||||||||||||||||||||||||||
| (Data in thousands, except per share data) | ||||||||||||||||||||||||||||||||||||||
Nine Months Ended December 30, 2023: | Gross profit | Operating expenses | Operating income | Provision for income taxes | Net income | Earnings per diluted share | ||||||||||||||||||||||||||||||||
| Reported | $ | 515,642 | $ | 380,702 | $ | 134,940 | $ | 31,260 | $ | 97,191 | $ | 1.89 | ||||||||||||||||||||||||||
| Amortization of acquired intangible assets | — | (21,606) | 21,606 | 5,482 | 16,124 | 0.31 | ||||||||||||||||||||||||||||||||
| Integration and transaction costs | — | (7,768) | 7,768 | 284 | 7,484 | 0.15 | ||||||||||||||||||||||||||||||||
| Restructuring costs | 7,329 | (714) | 8,043 | 1,761 | 6,282 | 0.12 | ||||||||||||||||||||||||||||||||
| Restructuring related costs | 3,604 | (2,950) | 6,554 | 1,604 | 4,950 | 0.09 | ||||||||||||||||||||||||||||||||
| Digital transformation costs | — | (10,712) | 10,712 | 2,609 | 8,103 | 0.16 | ||||||||||||||||||||||||||||||||
| Impairment of assets and PCS2 related charges | 219 | (402) | 621 | 157 | 464 | 0.01 | ||||||||||||||||||||||||||||||||
| MDR and IVDR costs | — | (4,587) | 4,587 | 1,077 | 3,510 | 0.07 | ||||||||||||||||||||||||||||||||
| Litigation-related charges | — | (6,684) | 6,684 | 1,684 | 5,000 | 0.10 | ||||||||||||||||||||||||||||||||
| Impairment of intangible assets | — | (10,419) | 10,419 | 3,376 | 7,043 | 0.14 | ||||||||||||||||||||||||||||||||
| Discrete tax items | — | — | — | (1,466) | 1,466 | 0.03 | ||||||||||||||||||||||||||||||||
| Adjusted | $ | 526,794 | $ | 314,860 | $ | 211,934 | $ | 47,828 | $ | 157,617 | $ | 3.07 | ||||||||||||||||||||||||||
| Adjusted, as a percentage of net revenues | 54.5 | % | 32.6 | % | 21.9 | % | 16.3 | % | ||||||||||||||||||||||||||||||
Nine Months Ended December 31, 2022: | Gross profit | Operating expenses | Operating income | Provision for income taxes | Net income | Earnings per diluted share | ||||||||||||||||||||||||||||||||
| Reported | $ | 458,848 | $ | 338,070 | $ | 120,778 | $ | 22,759 | $ | 86,018 | $ | 1.67 | ||||||||||||||||||||||||||
| Amortization of acquired intangible assets | — | (24,666) | 24,666 | 7,200 | 17,466 | 0.34 | ||||||||||||||||||||||||||||||||
| Integration and transaction costs | — | 425 | (425) | (134) | (291) | (0.01) | ||||||||||||||||||||||||||||||||
| Restructuring costs | (226) | (391) | 165 | 48 | 117 | — | ||||||||||||||||||||||||||||||||
| Restructuring related costs | 6,161 | (4,471) | 10,632 | 3,016 | 7,616 | 0.14 | ||||||||||||||||||||||||||||||||
| Impairment of assets and PCS2 related charges | (470) | (201) | (269) | (70) | (199) | — | ||||||||||||||||||||||||||||||||
| MDR and IVDR costs | 101 | (8,074) | 8,175 | 2,222 | 5,953 | 0.12 | ||||||||||||||||||||||||||||||||
| Litigation-related charges | — | (1,151) | 1,151 | 340 | 811 | 0.02 | ||||||||||||||||||||||||||||||||
| Gain on divestiture | — | 382 | (382) | (116) | (266) | (0.01) | ||||||||||||||||||||||||||||||||
| Discrete tax adjustments | — | — | — | 756 | (756) | (0.01) | ||||||||||||||||||||||||||||||||
| Adjusted | $ | 464,414 | $ | 299,923 | $ | 164,491 | $ | 36,021 | $ | 116,469 | $ | 2.26 | ||||||||||||||||||||||||||
| Adjusted, as a percentage of net revenues | 53.7 | % | 34.7 | % | 19.0 | % | 13.5 | % | ||||||||||||||||||||||||||||||
12